Abstract | BACKGROUND: AIM: METHODS: This was a single-centre, randomized, single-blind, vehicle-controlled pilot study in adult patients (n = 46) with 4 weeks of treatment and 4 weeks of follow-up. Efficacy was assessed clinically using the Investigator's Global Assessment ( IGA) and the Perioral Dermatitis Severity Index (PODSI). Quality of life (QOL) was determined by the Dermatology Quality of Life Index (DLQI). RESULTS: PODSI was significantly lower in the praziquantel group than in the placebo (vehicle) group, both during treatment and period. Mean IGA score showed a statistically significant therapeutic advantage of praziquantel over placebo at week 4 (P < 0.001). The praziquantel group experienced a greater improvement in mean DLQI. No serious treatment-related adverse events occurred in either group. CONCLUSIONS:
|
Authors | M R Bribeche, V P Fedotov, A Jillella, V V Gladichev, D M Pukhalskaya |
Journal | Clinical and experimental dermatology
(Clin Exp Dermatol)
Vol. 39
Issue 4
Pg. 448-53
(Jun 2014)
ISSN: 1365-2230 [Electronic] England |
PMID | 24825135
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | © 2014 British Association of Dermatologists. |
Chemical References |
- Anti-Inflammatory Agents
- Praziquantel
|
Topics |
- Administration, Topical
- Adolescent
- Adult
- Anti-Inflammatory Agents
(administration & dosage, adverse effects)
- Dermatitis, Perioral
(drug therapy)
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Pilot Projects
- Praziquantel
(administration & dosage, adverse effects)
- Quality of Life
- Single-Blind Method
- Young Adult
|